|Bid||6.00 x 1400|
|Ask||9.60 x 1100|
|Day's range||8.04 - 9.04|
|52-week range||8.04 - 37.07|
|Beta (5Y monthly)||2.08|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||41.00|
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in January. G1’s Chief Executive Officer Jack Bailey and Chief Medical Officer Raj Malik, M.D. will participate in a fireside chat during the H.C. Wainwright BioConnect 2022 conference. The webcast of the fireside chat will become available at 7:00 AM EST on January
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of G1’s common stock to three employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”), and an aggregate of 50,200 shares of G1’s common stock to seven employees under the previously-announced G1 Therapeutics, Inc.